Fintel reports that on December 20, 2024, Chardan Capital initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) has earned an average recommendation of “Buy” from the eleven research firms that are covering the firm, MarketBeat.com reports.

Fintel reports that on December 20, 2024, Chardan Capital initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy recommendation. As of December 3, 2024, the average one-year price target ...

The latest insights into the mind-body connection and shamanic healing processes come from psychoneuroimmunology or psychosomatic medicine, which explores how the mind and emotions are linked to the ...

NEW YORK, December 19, 2024--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain ...

Oppenheimer analyst Francois Brisebois maintained a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $7.40.

Charles Schwab Investment Management Inc. grew its holdings in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) by 8.3% during the third quarter, Holdings Channel reports.

Mind Medicine (MNMD) announced that it will be added to the Nasdaq Biotechnology Index NBI , effective at market open on Monday, December 23. “2024 has been a transformational year for MindMed.